Hemispherx BioPharma (NYSEAMERICAN:HEB) has been given a $1.00 price target by analysts at Ascendiant Capital Markets in a research note issued on Friday, TipRanks reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock.
Shares of HEB stock traded down $0.01 during mid-day trading on Friday, hitting $0.14. 3,137,296 shares of the stock were exchanged, compared to its average volume of 2,607,680. Hemispherx BioPharma has a 12-month low of $0.13 and a 12-month high of $0.35.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its quarterly earnings data on Monday, April 1st. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04. The firm had revenue of $0.24 million for the quarter.
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Story: What is the Beige Book?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.